Health, Pharmaceutical and Biotechnology Alert: HRSA issues letter discussing ADAP 340B rebates; proposed rule expected
On 3 February 2014, the Office of Pharmacy Affairs (OPA) posted a letter to its 340B drug pricing programme website discussing 340B rebates paid to AIDS drug assistance programmes (ADAPs). OPA is part of the Health Resources and Services Administration (HRSA) and administers the 340B programme. The letter, which is not dated, is signed by HRSA administrator Doctor Wakefield.
The Wakefield letter addresses the ability of ADAPs, a type of 340B-covered entity, to claim 340B rebates from manufacturers when the ADAP does not itself purchase the drug but rather covers some amount of insurance-related cost sharing for the drug, in the form of an insurance premium, copayment or deductible expenditure. Notably, this letter appears to be the first time that the 340B programme itself has addressed this issue.
ADAPs are the only type of covered entity that can access the 340B discount via a rebate, an option created by HRSA in 1998 through a notice in the federal register…
If you are registered and logged in to the site, click on the link below to read the rest of the Hogan Lovells briefing. If not, please register or sign in with your details below.
News from Hogan Lovells
News from The Lawyer
Briefings from Hogan Lovells
The UK government supports the European Commission’s decision not to impose mandatory quotas; it favours a self-regulatory national level approach.
Equality between men and women was firmly addressed in Spain by a 2007 act on the effective equality between men and women.
Analysis from The Lawyer
When a firm shouts loudly about a landmark merger, as SJ Berwin did when it joined forces with King & Wood Mallesons, departures are always likely to come under the spotlight.
The Lawyer’s latest Top 50 litigation firms list shows that business for dispute specialists is roaring along while new in-depth detail reveals the winning strategies